Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$318.02 USD

318.02
972,363

+0.10 (0.03%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $318.06 +0.04 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

West Pharmaceutical (WST) Q2 Earnings Beat, HVP Drives Sales

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.

West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

West Pharmaceutical Services (WST) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 8.21% and 0.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Align Technology (ALGN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of 9.90% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Ethan Feller headshot

Worried About Market Froth? Buy These 3 Dividend Stocks

by Ethan Feller

If you are concerned about the massive rally in tech leading to sharp corrections, then taking profits or adding other positions may be a prudent move

West Pharmaceutical Services (WST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Indrajit Bandyopadhyay headshot

5 Stocks to Buy From the Prospering Dental Supplies Industry

by Indrajit Bandyopadhyay

Here we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, ALGN, COO, XRAY and PDCO.

Sweta Killa headshot

S&P 500 Reclaims 4,500 Level: 5 Best Stocks in ETF

by Sweta Killa

The S&P 500 Index reached 4,500 for the first time in more than 15 months We have highlighted five stocks in ETF from different sectors that have gained more than 50% this year and have a Zacks Rank #1 (Strong Buy) or #2 (Buy).

West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL

by Zacks Equity Research

Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.

Veeva (VEEV) Falls Nearly 3% on Morgan Stanley Downgrade

by Zacks Equity Research

Veeva's (VEEV) shares lose nearly 3% after Morgan Stanley downgrades the stock to underweight, citing potential revenue loss from Salesforce's entry into the Life Sciences customer relationship management market.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Cardinal Health (CAH) to Build Distribution Center in Greenville

by Zacks Equity Research

Cardinal Health's (CAH) new facility will be its largest at-Home Solutions distribution center that will support business growth by providing new space and automation.

CONMED (CNMD) Stock Hits 52-Week High: Will It Continue?

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism in investors due to its broad product spectrum.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Revvity (RVTY) Launches Single Solution for Drug Development

by Zacks Equity Research

Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.

Penumbra (PEN) Launches New Technology for Blood Clot Removal

by Zacks Equity Research

Penumbra (PEN) launches Lightning Bolt 7, a new technology that can remove blood clots faster and more efficiently with modulated aspiration.

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Revvity (RVTY) Launches New System for Autoimmune Diagnostics

by Zacks Equity Research

Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.

Cooper Companies (COO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.